Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Hikma Pharmaceuticals ( (GB:HIK) ) has provided an announcement.
Hikma Pharmaceuticals has continued executing its previously announced $250 million share repurchase programme, buying back 553,384 ordinary shares between 11 and 15 May 2026 on the London Stock Exchange and Cboe Europe at prices around 1,400 to 1,450 pence per share. The company plans to cancel these shares, which will reduce the number of ordinary shares in issue and leave 215,497,758 shares carrying voting rights, a move that effectively returns capital to shareholders and may enhance earnings per share.
Since the programme’s launch in late February, Hikma has repurchased 6,388,695 shares at a total cost of £83 million while retaining 12,833,233 shares in treasury, underscoring an active capital management strategy. By shrinking its free-float through cancellations and maintaining a sizeable treasury position, Hikma is signalling confidence in its financial position and providing potential support to its share price, a development closely watched by investors in the pharmaceuticals sector.
The most recent analyst rating on (GB:HIK) stock is a Buy with a £1870.00 price target. To see the full list of analyst forecasts on Hikma Pharmaceuticals stock, see the GB:HIK Stock Forecast page.
Spark’s Take on HIK Stock
According to Spark, TipRanks’ AI Analyst, HIK is a Neutral.
The score is held back primarily by weakening cash generation and a notably bearish technical trend (oversold and trading below key moving averages). These are partially offset by attractive valuation (low P/E and strong dividend yield) and a constructive earnings-call outlook supported by guidance comfort and a GBP 250m buyback, despite near-term injectable headwinds.
To see Spark’s full report on HIK stock, click here.
More about Hikma Pharmaceuticals
Hikma Pharmaceuticals is a multinational generic and specialty pharmaceuticals company listed in London and on Nasdaq Dubai. It focuses on developing, manufacturing and marketing injectable, branded and non-injectable generic medicines for hospitals and healthcare providers in global markets, with a strong presence in the Middle East and North Africa as well as the U.S. and Europe.
Average Trading Volume: 1,372,096
Technical Sentiment Signal: Hold
Current Market Cap: £3.09B
See more data about HIK stock on TipRanks’ Stock Analysis page.